市場調查報告書

北美、歐洲、亞太地區的合法大麻市場規模、佔有率、趨勢分析:2020年∼2026年

North America, Europe & Asia Pacific Legal Cannabis Market Size, Share & Trends Analysis Report By Product Type (Hemp Oil, Marijuana), By Application, By Region, And Segment Forecasts, 2020 - 2026

出版商 Grand View Research, Inc. 商品編碼 948117
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
價格
北美、歐洲、亞太地區的合法大麻市場規模、佔有率、趨勢分析:2020年∼2026年 North America, Europe & Asia Pacific Legal Cannabis Market Size, Share & Trends Analysis Report By Product Type (Hemp Oil, Marijuana), By Application, By Region, And Segment Forecasts, 2020 - 2026
出版日期: 2020年06月30日內容資訊: 英文 100 Pages
簡介

北美、歐洲、亞太地區的合法大麻市場規模,預計至2026年達到677億美元,在預測期間內以年複合成長率19.6%的速度成長。醫療用Marijuana的需求增加,加上Hemp、Marijuana產品的採用增加,預計推動市場成長。

本報告提供北美、歐洲、亞太地區的合法大麻市場相關調查分析,市場概要,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 合法大麻市場:變數、趨勢、範圍

  • 大麻用戶估計數:各國
  • 合法大麻的法規方案:各國
  • 市場動態
  • 產業分析 - SWOT分析:各要因
  • 大麻素概要
  • 攝取方法分析
  • 大麻的價格分析:各國

第3章 合法大麻市場:各產品類型估計、趨勢分析

  • 市場定義
  • 合法大麻市場:各產品類型趨勢分析
  • 合法大麻市場:產品類型分析
    • Hemp油(植物全體/CBD油)
    • Marijuana

第4章 大麻的機會分析

  • 慢性疼痛
  • 發炎
  • 焦慮症

第5章 合法大麻市場:各用途估計、趨勢分析

  • 合法大麻市場:各用途趨勢分析
  • 合法大麻市場:用途分析
    • 醫療用
    • B2B通道
    • 成人用

第6章 合法大麻市場:各地區的估計、趨勢分析

  • 合法大麻市場:各國分析
    • 美國
    • 加拿大
    • 德國
    • 義大利
    • 波蘭
    • 捷克
    • 瑞士
    • 荷蘭
    • 澳洲
    • 紐西蘭
    • 日本
    • 韓國
    • 泰國

第7章 大麻製劑市場估計、趨勢分析

  • 大麻製劑市場
    • 歐洲
    • 亞太地區

第8章 大麻營養食品市場估計、趨勢分析

  • 營養食品市場定義
  • 大麻營養食品市場
    • 亞太地區

第9章 競爭情形

  • 企業簡介:國際企業
  • 企業簡介:ASX上市公司

第10章 調查手法和範圍

目錄
Product Code: GVR-4-68038-768-1

North America, Europe & Asia Pacific Legal Cannabis Market Growth & Trends

The North America, Europe, and Asia Pacific legal cannabis market size is anticipated to reach USD 67.7 billion by 2026, registering a CAGR of 19.6% during the forecast period, according to a new report by Grand View Research, Inc. The increased adoption of hemp and marijuana products coupled with the rising demand for medical marijuana is anticipated to drive the market growth. Furthermore, the impending legalization of marijuana for adult use is an important factor supporting the growth over the forecast period.

Based on product type, marijuana dominated the market with a revenue share of USD 96.6% in 2019. The use of marijuana for medical purposes is gaining momentum owing to recent legalizations in various countries. Marijuana is used for the treatment of patients with chronic conditions such as Parkinson's disease, cancer, arthritis, Alzheimer's disease, neurologic problems like depression, anxiety, epilepsy, and others. Thus, wide application of marijuana for the treatment of various chronic conditions is one of the major factors driving the growth of this segment.

Based on application, medical use segment dominated the market with the revenue share of 66.0% in 2019. The medical use of cannabis is legal in a greater number of countries as compared to adult-use, owing to which the segment is expected to remain dominant throughout the forecast period. On the other hand, B2B channels segment is expected to witness the fastest CAGR over the forecast period. The growing use of cannabis and its derivates in various applications areas such as pharmaceuticals, nutraceuticals, personal care and cosmetics, and edibles, is anticipated to boost the demand for these products.

North America dominated the market in 2019 with a revenue share of 91.0%. The early legalization of marijuana for medical and adult-use and the presence of a large customer pool in the region are the key factors driving the market growth. On the other hand, Asia Pacific is expected to be the fastest-growing region, owing to rising awareness regarding the medical and health benefits of cannabis, encouraging the Asian countries to legalize cannabis and its derivatives.

North America, Europe & Asia Pacific Legal Cannabis Market Report Highlights

Marijuana emerged as leading product segment in 2019 with a revenue share of 96.6%, owing to the growing adoption of marijuana for various medical conditions

B2B channel is anticipated to be the fastest-growing application segment, owing to the increasing use of cannabinoids for a wide range of industries

North America accounted for the largest share, owing to the higher consumption rate due to legal acceptance of cannabis

Some of the key players include Aphria, Inc.; Canopy Growth Corporation, Aurora Cannabis, Maricann Group, Inc.; ABcann Medicinals, Inc.; Tilray, The Cronos Group, GW Pharmaceuticals, plc., Organigram Holding, Inc.; and Lexaria Bioscience Corp

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Market Summary

Chapter 2 Legal Cannabis Market: Variables, Trends & Scope

  • 2.1 Estimated Number of Cannabis Users from 2016 to 2026, by Country
    • 2.1.1 Estimated Number of Medical Marijuana Users from 2016 to 2026, by Country
  • 2.2 Legal Cannabis Regulatory Scenario, By Country
    • 2.2.1 Australia
      • 2.2.1.1 Overview
      • 2.2.1.2 Cultivation
      • 2.2.1.3 Manufacturing
      • 2.2.1.4 Regulatory Bodies Involved
    • 2.2.2 U.S.
      • 2.2.2.1 Overview
      • 2.2.2.2 Cultivation
      • 2.2.2.3 Regulatory Bodies Involved
    • 2.2.3 Canada
      • 2.2.3.1 Overview
      • 2.2.3.2 Cultivation
      • 2.2.3.3 Production
      • 2.2.3.4 Regulatory Bodies Involved
    • 2.2.4 Germany
      • 2.2.4.1 Overview
      • 2.2.4.2 Cultivation/Production
      • 2.2.4.3 Regulatory Bodies Involved
    • 2.2.5 Italy
      • 2.2.5.1 Overview
      • 2.2.5.2 Cultivation
      • 2.2.5.3 Regulatory Bodies Involved
    • 2.2.6 The Netherlands
      • 2.2.6.1 Overview
      • 2.2.6.2 Cultivation
      • 2.2.6.3 Regulatory Bodies Involved
    • 2.2.7 Czech Republic
      • 2.2.7.1 Overview
      • 2.2.7.2 Cultivation/Production
      • 2.2.7.3 Regulatory Bodies Involved
    • 2.2.8 Poland
      • 2.2.8.1 Overview
      • 2.2.8.2 Cultivation/Production
      • 2.2.8.3 Regulatory Bodies Involved
    • 2.2.9 Switzerland
      • 2.2.9.1 Overview
      • 2.2.9.2 Cultivation/Production
      • 2.2.9.3 Regulatory Bodies Involved
    • 2.2.10 New Zealand
      • 2.2.10.1 Overview
      • 2.2.10.2 Cultivation/Production
      • 2.2.10.3 Regulatory Bodies Involved
    • 2.2.11 Thailand
      • 2.2.11.1 Overview
      • 2.2.11.2 Cultivation/Production
      • 2.2.11.3 Regulatory Bodies Involved
    • 2.2.12 Japan
      • 2.2.12.1 Overview
      • 2.2.12.2 Cultivation/Production
      • 2.2.12.3 Regulatory Bodies Involved
    • 2.2.13 South Korea
      • 2.2.13.1 Overview
      • 2.2.13.2 Cultivation/Production
      • 2.2.13.3 Regulatory Bodies Involved
  • 2.3 Market Dynamics
    • 2.3.1 Market Driver Analysis
      • 2.3.1.1 Growing legalization of medical marijuana in various countries
      • 2.3.1.2 Growing adoption of medical marijuana for treatment of chronic diseases
      • 2.3.1.3 Increasing demand of cannabis driving cannabis cultivation across the globe
      • 2.3.1.4 Elimination of black market through legalization of medical marijuana
      • 2.3.1.5 Impending legalization of marijuana for recreational/adult use
      • 2.3.1.6 Increasing need for potent cannabis and recent technological advancements
      • 2.3.1.7 Increasing preference towards cannabis extracts such as oils and tinctures
      • 2.3.1.8 Growing legalization of cannabis-based CBD products
      • 2.3.1.9 Growing adoption of CBD-based products for treating various medical conditions
      • 2.3.1.10 Rise in the number of retailers selling CBD-based products
    • 2.3.2 Market Restraint Analysis
      • 2.3.2.1 Absence of legalization programs in several Asian and African countries
      • 2.3.2.2 Strict government regulations
      • 2.3.2.3 Legalization of medical cannabis only for selected indications
      • 2.3.2.4 High pricing of medical cannabis
      • 2.3.2.5 High pricing of cannabis compared to illegal markets in the U.S.
      • 2.3.2.6 Illicit cananbis trade
    • 2.3.3 Industry Challenges
      • 2.3.3.1 Incomplete evidence regarding the effectiveness of medical marijuana
      • 2.3.3.2 Reluctance of doctors to prescribe cannabis
      • 2.3.3.3 Lower market access to cannabis due to absence of legalization programs, leading to smuggling
  • 2.4 Industry Analysis -SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
    • 2.4.1 Political and Legal Landscape
    • 2.4.2 Economic and Social Landscape
    • 2.4.3 Technology Landscape
  • 2.5 Cannabinoid Summary
    • 2.5.1 Cannabidiol (CBD)
    • 2.5.2 Tetrahydrocannabinol (THC)
    • 2.5.3 Cannbinol (CBN)
    • 2.5.4 CBG
    • 2.5.5 Terpenes
    • 2.5.6 Flavonoids
    • 2.5.7 cannabinoid Acids
    • 2.5.8 Entourage Effect
  • 2.6 Analysis on Mode of Ingestion
  • 2.7 Cannabis Pricing Analysis, By Country, 2019 - 2026 (USD)

Chapter 3 Legal Cannabis Market: Product Type Estimates & Trend Analysis

  • 3.1 Market Definition
  • 3.2 Legal Cannabis Market: Product Type Movement Analysis
  • 3.3 Legal Cannabis Market: Product Type Analysis
    • 3.3.1 Hemp Oil (Whole Plant/CBD Oil)
      • 3.3.1.1 Hemp Oil (Whole Plant/CBD Oil) Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 3.3.2 Marijuana
      • 3.3.2.1 Marijuana Market Estimates and Forecasts, 2016 - 2026 (USD Million)
      • 3.3.2.2 Flower
      • 3.3.2.3 Oil
      • 3.3.2.4 Tincture

Chapter 4 Cannabis Opportunity Analysis

  • 4.1 Chronic Pain
    • 4.1.1 Global Chronic Pain Therapeutics Market Estimates, Forecasts & Trends Analysis, 2016 - 2026
    • 4.1.2 Global Opioid Market Estimates, Forecasts & Trends Analysis, 2016 - 2026
    • 4.1.3 Estimated Number of Opioid Users from 2016 to 2026, by Country
    • 4.1.4 Estimated Number of Chronic Pain Patients from 2016 to 2026, by Country
    • 4.1.5 Comparative Analysis on the use of Cannabis Vs Opioid in Chronic Pain
    • 4.1.6 Economic Cost Analysis on Opioid Misuse, by Country
      • 4.1.6.1 U.S.
      • 4.1.6.2 Canada
      • 4.1.6.3 Germany
      • 4.1.6.4 Italy
      • 4.1.6.5 Poland
      • 4.1.6.6 Czech Republic
      • 4.1.6.7 Switzerland
      • 4.1.6.8 Netherlands
      • 4.1.6.9 Australia
      • 4.1.6.10 New Zealand
      • 4.1.6.11 Thailand
      • 4.1.6.12 Japan
      • 4.1.6.13 South Korea
  • 4.2 Inflammation
    • 4.2.1 Global Inflammation Therapeutics Market Size 2016 to 2026
    • 4.2.2 Estimated Number of Inflammation Patients, from 2016 to 2026, by Country
    • 4.2.3 Comparative Analysis on the use of Cannabis Vs Inflammation Therapeutics
  • 4.3 Anxiety
    • 4.3.1 Global Anxiety Therapeutics Market Size 2016 to 2026
    • 4.3.2 Estimated Number of Anxiety Patients, from 2016 to 2026, by Country
    • 4.3.3 Comparative Analysis on the use of Cannabis Vs Anxiety Therapeutics in Anxiety Patients

Chapter 5 Legal Cannabis Market: Application Estimates & Trend Analysis

  • 5.1 Legal Cannabis Market: Application Movement Analysis
  • 5.2 Legal Cannabis Market: Application Analysis
    • 5.2.1 Medical Use
      • 5.2.1.1 Medical Use Market Estimates and Forecasts, 2016 - 2026 (USD Million)
      • 5.2.1.2 Chronic Pain
      • 5.2.1.3 Anxiety
      • 5.2.1.4 Inflammation
      • 5.2.1.5 Sleep Disorders
      • 5.2.1.6 Others
    • 5.2.2 B2B Channel
      • 5.2.2.1 B2B Channel Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 5.2.3 Adult Use
      • 5.2.3.1 Adult use Market Estimates and Forecasts, 2016 - 2026 (USD Million)

Chapter 6 Legal Cannabis Market: Regional Estimates & Trend Analysis

  • 6.1 Legal Cannabis Market: Country Analysis, 2019 & 2026
    • 6.1.1 U.S.
      • 6.1.1.1 U.S. Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.2 Canada
      • 6.1.2.1 Canada Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.3 Germany
      • 6.1.3.1 Germany Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.4 Italy
      • 6.1.4.1 Italy Legal Cannabis Market Estimates And Forecasts, 2016 - 2026 (USD Million)
    • 6.1.5 Poland
      • 6.1.5.1 Poland Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.6 Czech Republic
      • 6.1.6.1 Czech Republic Legal Cannabis Market Estimates And Forecasts, 2016 - 2026 (USD Million)
    • 6.1.7 Switzerland
      • 6.1.7.1 Switzerland Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.8 Netherlands
      • 6.1.8.1 Netherlands Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.9 Australia
      • 6.1.9.1 Australia Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.10 New Zealand
      • 6.1.10.1 New Zealand Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.11 Japan
      • 6.1.11.1 Japan Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.12 South Korea
      • 6.1.12.1 South Korea Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)
    • 6.1.13 Thailand
      • 6.1.13.1 Thailand Legal Cannabis Market Estimates and Forecasts, 2016 - 2026 (USD Million)

Chapter 7 Cannabis Pharmaceuticals Market Estimates & Trend Analysis

  • 7.1 Cannabis Pharmaceuticals Market
    • 7.1.1 Europe
      • 7.1.1.1 Germany
      • 7.1.1.2 Italy
      • 7.1.1.3 Netherlands
      • 7.1.1.4 Poland
      • 7.1.1.5 Czech Republic
      • 7.1.1.6 Switzerland
    • 7.1.2 Asia Pacific
      • 7.1.2.1 Australia
      • 7.1.2.2 New Zealand
      • 7.1.2.3 South Korea
      • 7.1.2.4 Japan

Chapter 8 Cannabis Nutraceuticals Market Estimates & Trend Analysis

  • 8.1 Nutraceutical Market Definition
  • 8.2 Cannabis Nutraceuticals Market
    • 8.2.1 Asia Pacific
      • 8.2.1.1 Australia
      • 8.2.1.2 New Zealand
      • 8.2.1.3 Thailand
      • 8.2.1.4 Japan
      • 8.2.1.5 South Korea

Chapter 9 Competitive Landscape

  • 9.1 Company Profiles: International Players
    • 9.1.1 Canopy Growth Corporation
      • 9.1.1.1 Company overview
      • 9.1.1.2 Financial performance
      • 9.1.1.3 Strategic initiatives
    • 9.1.2 Aphria, Inc
      • 9.1.2.1 Company overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Strategic initiatives
    • 9.1.3 Aurora Cannabis
      • 9.1.3.1 Company overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Strategic initiatives
    • 9.1.4 Tilray
      • 9.1.4.1 Company overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Strategic initiatives
    • 9.1.5 GW Pharmaceuticals, plc.
      • 9.1.5.1 Company overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Strategic initiatives
    • 9.1.6 Organigram holdings Inc.
      • 9.1.6.1 Company overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Strategic initiatives
    • 9.1.7 Lexaria Bioscience Corp.
      • 9.1.7.1 Company overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Strategic Initiatives
    • 9.1.8 ABcann Medicinals Inc. (PArt of VIVO Cannabis Inc.)
      • 9.1.8.1 Company overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Strategic Initiatives
    • 9.1.9 The Cronos Group
      • 9.1.9.1 Company overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Strategic Initiatives
  • 9.2 Company Profiles: ASX Listed Cannabis Companies
    • 9.2.1 AusCann Group Holdings Pty Ltd
      • 9.2.1.1 Company overview
      • 9.2.1.2 Strategic initiatives
    • 9.2.2 Cann Group Ltd.
      • 9.2.2.1 Company overview
      • 9.2.2.2 Financial performance
      • 9.2.2.3 Strategic initiatives
    • 9.2.3 Bod Australia
      • 9.2.3.1 Company Overview
      • 9.2.3.2 Financial Performance
      • 9.2.3.3 Strategic Initiatives
    • 9.2.4 Zelira Therapeutics
      • 9.2.4.1 Company Overview
      • 9.2.4.2 Strategic Initiatives
    • 9.2.5 Althea Group Holdings Limited
      • 9.2.5.1 Company Overview
      • 9.2.5.2 Financial Performance
      • 9.2.5.3 Strategic Initiatives
    • 9.2.6 THC Global Group Ltd
      • 9.2.6.1 Company Overview
      • 9.2.6.2 Financial Performance
      • 9.2.6.3 Strategic Initiatives
    • 9.2.7 MGC Pharmaceuticals Ltd
      • 9.2.7.1 Company Overview
      • 9.2.7.2 Financial Performance
      • 9.2.7.3 Strategic Initiatives
    • 9.2.8 Ecofibre Limited
      • 9.2.8.1 Company Overview
      • 9.2.8.2 Financial Performance
      • 9.2.8.3 Strategic Initiatives

Chapter 10 Methodology and Scope

  • 10.1 Research Methodology
    • 10.1.1 Information procurement
  • 10.2 Information or Data Analysis
  • 10.3 Market Formulation & Validation
    • 10.3.1 Region Market: CAGR Calculation
  • 10.4 Region Based Segment Share Calculation
  • 10.5 List of Secondary Sources
  • 10.6 List of Primary Sources

List of Tables

  • Table 1 Cannabis user pool analysis, by country, 2016 - 2026 (in thousands)
  • Table 2 Medical marijuana users pool analysis, by country, 2016 - 2026
  • Table 3 Average price of Marijuana per mg, by country, 2019 - 2026 (USD)
  • Table 4 Average price of Hemp CBD per mg, by country, 2019 - 2026 (USD)
  • Table 5 Opioid users pool analysis, by country, 2016 - 2026 (in thousands)
  • Table 6 Chronic pain patients, by country, 2016 - 2026 (in thousands)
  • Table 7 Inflammation patients, by country, 2016 - 2026 (in thousands)
  • Table 8 Anxiety patients, by country, 2016 - 2026 (in thousands)
  • Table 9 Europe cannabis pharmaceuticals market, by country, 2016 - 2026 (USD Million)
  • Table 10 Asia Pacific cannabis pharmaceuticals market, by country, 2016 - 2026 (USD Million)
  • Table 11 Australia cannabis nutraceuticals market, by product type, 2016 - 2026 (USD Million)
  • Table 12 New Zealand cannabis nutraceuticals market, by product type, 2016 - 2026 (USD Million)
  • Table 13 Thailand cannabis nutraceuticals market, by product type, 2016 - 2026 (USD Million)
  • Table 14 Japan cannabis nutraceuticals market, by product type, 2016 - 2026 (USD Million)
  • Table 15 South Korea cannabis nutraceuticals market, by product type, 2016 - 2026 (USD Million)
  • Table 16 Partial list of secondary sources
  • Table 17 Partial list of primary sources

List of Figures

  • Fig. 1 Global legal cannabis market snapshot, 2019 (USD Million)
  • Fig. 2 Legal cannabis market drivers impact analysis
  • Fig. 3 Effect of cannabis smoking vs. cannabis consumption
  • Fig. 4 Legal cannabis market restraints impact analysis
  • Fig. 5 Global cannabis derived products mode of ingestion analysis, 2019-2026
  • Fig. 6 Legal cannabis market, product type outlook: Key takeaways
  • Fig. 7 Legal cannabis market segmentation
  • Fig. 8 Legal cannabis market: Product type movement analysis (2019 & 2026) (USD Million)
  • Fig. 9 Hemp Oil (Whole Plant/CBD Oil) market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 10 Marijuana market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 11 Flower market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 12 Oil market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 13 Tinctures market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 14 Global chronic pain therapeutics market, regional outlook: Key takeaways
  • Fig. 15 Chronic pain therapeutics market share, by region (2019 & 2026) (%)
  • Fig. 16 Global opioid market, regional outlook: Key takeaways
  • Fig. 17 Opioid market share, by region (2019 & 2026) (%)
  • Fig. 18 Global inflammation therapeutics market, regional outlook : Key takeaways
  • Fig. 19 Inflammation therapeutics market share, by region (2019 & 2026) (%)
  • Fig. 20 Global anxiety therapeutics market, regional outlook : Key takeaways
  • Fig. 21 Anxiety therapeutics market share, by region (2019 & 2026) (%)
  • Fig. 22 Legal cannabis market, application outlook: Key takeaways
  • Fig. 23 Legal cannabis market: Application movement analysis (2019 & 2026)
  • Fig. 24 Medical use market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 25 Chronic pain market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 26 Anxiety market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 27 Inflammation market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 28 Sleep Disorders market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 30 B2B channel market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 31 Adult use market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 32 U.S. legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 33 Canada legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 34 Germany legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 35 Italy legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 36 Poland legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 37 Czech Republic legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 38 Switzerland legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 39 Netherlands legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 40 Australia legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 41 New Zealand legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 42 Japan legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 43 South Korea legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 44 Thailand legal cannabis market estimates and forecasts, 2016 - 2026 (USD Million)
  • Fig. 45 Europe cannabis pharmaceuticals market share, 2019 & 2026 (%)
  • Fig. 46 Germany cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 47 Italy cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 48 Netherlands cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 49 Poland cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 50 Czech Republic cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 51 Switzerland cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 52 Asia Pacific cannabis nutraceuticals market share, 2019 & 2026 (%)
  • Fig. 53 Australia cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 54 New Zealand cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 55 South Korea cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 56 Japan cannabis pharmaceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 57 Asia Pacific cannabis nutraceuticals market share, 2019 & 2026 (%)
  • Fig. 58 Australia cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 59 New Zealand cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 60 Thailand cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 61 Japan cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 62 South Korea cannabis nutraceuticals market estimates & forecasts, 2016 - 2026 (USD Million)
  • Fig. 63 Market research process
  • Fig. 64 Information procurement
  • Fig. 65 Primary research pattern
  • Fig. 66 Market research approaches
  • Fig. 67 Value chain based sizing & forecasting
  • Fig. 68 QFD modelling for market share assessment
  • Fig. 69 Market formulation & validation